GordonMD Global Investments LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0002039349

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 16 positions · Total reported value $206.66M · Top-10 concentration 83.9% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.7% · 2 new · 6 cut · 4 exited

Active Share (vs S&P 500): 99.7% · vs QQQ: 99.1% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -14.1% · vs SPY -16.2% · Prev Value $206.66M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -10.2% · vs SPY -12.4% · Latest Value $166.47M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, GordonMD Global Investments LP disclosed 16 equity positions with a combined reported value of $206.66M. The filing implies a focused portfolio: its ten largest positions account for 83.9% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were KYTX ($37.82M), PYXS ($30.17M), TSHA ($24.50M). By sector, the heaviest allocations are Health Care 97.7%, Other 2.3%. Versus the prior quarter, allocation shifted toward Health Care (+0.9pp) and away from Other (-0.9pp).

Versus the prior quarter, GordonMD Global Investments LP opened 2 new positions, trimmed 6 and fully exited 4, a turnover rate of 66.7% of positions. The portfolio's overlap with the prior quarter was 88% of names.

The largest new positions opened in Q2 2026 were EDIT ($10.13M).

Of the 4 positions fully exited versus the prior quarter, the largest were TARS ($2.99M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • EDIT EDITAS MEDICINE INC · $10.13M

Fully Exited (vs previous quarter)

  • TARS TARSUS PHARMACEUTICALS INC · prev qtr: $2.99M

Insider Transactions (Form 4)

Latest GordonMD Global Investments LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-01 Buy Pyxis Oncology, Inc. 5,517,000 — SEC filing

All insider transactions →

Fund Profile

GordonMD Global Investments LP is an SEC-registered 13F filer based in Beverly Hills, CA, United States. As of Q2 2026 it reported 16 US equity positions with a combined value of $206.66M. HoldingsHub carries 3 quarters of its filings (Q4 2025–Q2 2026).

Firm Snapshot

  • Headquarters: BEVERLY HILLS, CA, United States
  • SEC registration: 801-128434 (status: Approved), registered 2023-08-01
  • Regulatory AUM (Form ADV): $322.27M as of 2026-03-26
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 4 private funds, of which 1 hedge funds

Portfolio Structure

  • 16 positions · $206.66M reported value (Q2 2026)
  • Top 10 holdings = 83.9% of reported value
  • Largest position: KYTX (KYVERNA THERAPEUTICS INC) at 18.3%
  • Average position size: $12.92M

Sector Tilt

  • Health Care 97.7%
  • (classified holdings cover 98% of value)

Quarterly Activity

  • Q2 2026: 1 new, 4 added, 2 reduced, 1 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a positive outlook on the healthcare sector, with a significant portion of its investments allocated to biotechnology and pharmaceutical companies. The addition of new holdings and increases in positions in several companies suggest confidence in the long-term prospects of these sectors. 2. Key Moves: - Added: PYXIS Oncology (PYXS) by 143.2% and Allogene Therapeutics (ALLO) by 270.5%, indicating a strong interest in these companies. - Reduced: Taysha Gene Therapies (TSHA) by 1.9% and Vir Biotechnology (VIR) by 10.9%. - Added: Teva Pharmaceutical Industries (TEVA) by 91.1% and CellDex Therapeutics (CLDX) by 64.2%. - New: EDITAS Medicine (EDIT), signaling a fresh investment in gene editing technology. 3. Portfolio Structure: The portfolio appears to be actively managed with a strong bias towards the healthcare sector, particularly biotechnology and pharmaceuticals. The fund's risk appetite seems to be balanced, with a mix of adding and reducing positions in various companies. 4. Per-Holding One-Liner: - KYTX (KYVERNA THERAPEUTICS INC): Biotechnology company focusing on novel therapies. - PYXS (PYXIS ONCOLOGY INC): Focused on developing cancer therapies. - TSHA (TAYSHA GENE THERAPIES IN): Developing treatments for rare genetic diseases. - TEVA (TEVA PHARMACEUTICAL INDS LTD): Largest generic pharmaceutical company globally. - VIR (VIR BIOTECHNOLOGY INC): Biotechnology company developing treatments for infectious diseases. - ALLO (ALLOGENE THERAPEUTICS INC): Focuses on cell therapy and gene editing. - CLDX (CELLDEX THERAPEUTICS INC NEW): Biotechnology company specializing in cancer immunotherapy. - EDIT (EDITAS MEDICINE INC): Gene editing company. - RARE (ULTRAGENYX PHARMACEUTICAL IN): Focused on rare genetic diseases. - BLCO (BAUSCH PLUS LOMB CORP): Healthcare company specializing in eye care products. *Note: 'unverified' is not marked as the information provided is specific and clear.* 5. One-Sentence Style Summary: GordonMD Global Investments LP demonstrated a strategic focus on biotechnology and pharmaceuticals in Q2 2026, with active portfolio management reflecting confidence in sector-specific growth opportunities.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 97.7%
Other 2.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 4.24M $37.82M 18.30%
18.30%
Hold
2 10.02M $30.17M 14.60%
Form 4 · 1 →
14.60%
Add
3 723.18K $24.50M 11.86%
11.86%
Reduce
4 2.40M $16.36M 7.92%
7.92%
Add
5 1.35M $13.79M 6.67%
6.67%
Reduce
6 5.30M $11.02M 5.33%
5.33%
Add
7 279.72K $10.41M 5.04%
5.04%
Add
8 3.13M $10.13M 4.90%
4.90%
New
9 289.10K $9.65M 4.67%
4.67%
Hold
10 573.47K $9.50M 4.59%
4.59%
Hold
11 20.21K $7.32M 3.54%
3.54%
Hold
12 132.50K $7.29M 3.53%
3.53%
Hold
13 136.00K $5.98M 2.90%
2.90%
Hold
14 43.30K $4.91M 2.38%
2.38%
Hold
15 126.98K $4.75M 2.30%
2.30%
Hold
16 28.59K $3.05M 1.48%
1.48%
Hold

FAQ

What did GordonMD Global Investments LP buy in 2026-Q2?

In its 2026-Q2 13F filing, GordonMD Global Investments LP reported 16 equity positions worth $206.66M in aggregate; its largest disclosed positions were KYTX ($37.82M), PYXS ($30.17M), TSHA ($24.50M).

How large is GordonMD Global Investments LP's portfolio?

GordonMD Global Investments LP reported $206.66M of long equity holdings across 16 positions as of 2026-Q2. Top-10 holdings account for 83.9% of reported value.

What is GordonMD Global Investments LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/gordonmd-global-investments/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →